Introduction
The oncometabolite alpha-hydroxyglutaric acid (2-hydroxyglutarate, 2HG) has attracted increasing interest in recent years. Monoallelic point mutations in the enzyme isocitrate dehydrogenase (IDH), which occur amongst others in gliomas, 1 glioblastoma, 2 and acute myeloid leukemia (AML), 3 lead to a lossof-function regarding conversion of isocitrate to a-ketoglutarate (aKG) and a gain-of-function in terms of reducing aKG to the D-enantiomer of 2HG (D-2HG). 4, 5 Several studies have aimed to delineate the (autocrine) effects of D-2HG on tumor cells. It has been shown that D-2HG is a competitive inhibitor of aKG-dependent dioxygenases (such as histone demethylases and the TET family of 5 mC hydroxylases) and its accumulation leads to profound epigenetic alterations 6 interfering with hematopoietic differentiation. 7 In fact, D-2HG is sufficient to promote leukemogenesis with the D-2HG-mediated transformation being reversible. [7] [8] [9] D-2HG abundance has also been linked to changes in the cellular redox equilibrium yielding an increased reactive oxygen species (ROS) production, with oxidative stress being one of the hallmarks of cancer. 10 In addition to redox metabolism, bioenergetic pathways also appear to be potential D-2HG targets: introducing mutant IDH and exogenous cell-permeable D-2HG application both promote glutamine metabolism in colorectal cancer cells. 11 Moreover, D-2HG has been shown to diminish mitochondrial respiration and respiration-coupled ATP production in glioblastoma cells. 12, 13 While most studies are focusing on tumor-directed D-2HG effects, its microenvironmental impact and, in particular, its role in AML-mediated immune modulation remains unexplored. To date, a number of immune escape mechanisms have been identified in AML and include depletion of (for activated T-cells) critical nutrients such as tryptophan 14 and/or the abundant production of immune regulatory metabolites such as ROS. 15 In fact, a recent study on gliomas suggested that D-2HG impairs CD8
C T-cell responses while using IDH inhibitors improved intrinsic antitumor immunity and enhanced the efficacy of a peptide vaccination-based therapy. 16 Accordingly, immune cell infiltration has been generally found decreased in mutant IDH gliomas as compared to their wild type counterparts. Another recent report demonstrated in a murine system that accumulation of endogenous D-2HG at physiological concentrations due to an enhanced transaminase activity led to a preferable Th17 over Treg differentiation by epigenetic interference. 17 Therefore, we were interested whether D-2HG (that can reach concentrations of 5-35 mmol/L in glioma tissue 18 and 2 -600 mmol/L in AML 19 patients' serum) holds potential immune regulatory properties by interfering with T-cell function. Our analyses revealed that D-2HG is efficiently taken up by T-cells. This is in accordance with our findings that D-2HG levels can be more than 1000-fold enriched in T-cells from patients with AML blasts that harbor mutant IDH as compared to (a) healthy controls and to (b) AML patients with wild-type IDH. Even at high D-2HG concentrations (of 20 mmol/L) viability, proliferation, and IFNg production were not negatively affected in T-cells. However, bioenergetics of activated T-cells shifted away from aerobic glycolysis towards respiration, which is at least partly explained by the observed D-2HG-triggered hypoxia inducible factor-1a (HIF-1a) destabilization. In line with previous findings that HIF-1a-dependent (aerobic) glycolysis orchestrates differentiation of Th17 cells, 20 we found a reduced Th17 polarization in the presence of D-2HG. Moreover, and in agreement with previous findings that regulatory T-cells (Tregs) rely on oxidative phosphorylation to meet their energetic demands frequencies of Tregs were increased upon D-2HG treatment. Taken together, we show for the first time that exogenous D-2HG has substantial immune metabolic effects on T-cells, establishing a sound basis for further exploring its role for tumor-associated immune modulation especially in view of potential therapeutic strategies. Different types of malignant cells (including gliomas,  21,22 AML,   5 and breast cancer 23 ) can abundantly produce and release D-2HG, which is then found in patients' sera or tumors more than 100-fold increased. 4, 24, 25 Thus, it is of particular interest whether immune cells such as T-cells take up tumor-derived D-2HG. Uptake of exogenously applied non-cell permeable D-2HG by purified healthy control-derived T-cells undergoing activation was evaluated using an enzymatic assay as previously described. 26 Intracellular D-2HG levels were found to be increased in a dosedependent manner showing that T-cells have the ability to enrich exogenous D-2HG (Fig. 1Ai) . Furthermore, mass spectrometric analysis revealed a significantly and highly elevated content of 2HG in two out of seven cases of T-cells derived from AML patients as compared to T-cells from healthy donors (HD) (Fig. 1Aii) . Notably, 2HG levels were increased in T-cells from AML patients carrying an IDH2 mutation (which represent approx. 10-30% of all AML patients). This finding corroborates the biological relevance of our in vitro model. Previously, it has been shown that intracellular D-2HG can influence proliferation 23 and viability 27 of tumor cells. Hence, effects of D-2HG on proliferation were evaluated by means of flow cytometry of T-cells (Fig. 1B) as well as thymidine incorporation in CD4
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C and CD8 C T-cell subsets (Supplemental Fig. 1 ), and on survival by Annexin V/7-AAD staining (Fig. 1C) . In fact, we could not detect an impairment of T-cell proliferation or an increase in cell death. However, T-cell receptor activation was slightly but significantly reduced in the presence of 20 mM D-2HG as indicated by the reduction of CD3z chain expression and Zap70 phosphorylation (Fig. 1D) . Activation markers such as CD25 and CD137 were downregulated, although statistical significance was only reached for CD25 expression (Fig. 1E ). However, a clear time-and dose-dependent effect of D-2HG on T-cell receptor activation could not be observed (Supplemental Fig. 2 ) unless doses reached toxic values (40 mM). As the observed effects were rather small and transient, we postulate that the general fitness of in vitro cultured T-cells and their ability to respond towards activating stimuli are not impaired by the presence of D-2HG. Nevertheless, there remains the possibility that effects provoked by D-2HG might be subliminal and that the downstream signaling might still be functional because it reaches a sufficient triggering threshold.
D-2HG enhances glucose uptake while skewing bioenergetics away from aerobic glycolysis towards respiration Activation, function, and differentiation of T-cells are highly dependent on their bioenergetic profile as recently reviewed by Palmer et al. 28 Activated T-cells (like cancer cells) undergo a metabolic switch from oxidative phosphorylation towards aerobic glycolysis to meet their energetic and biosynthetic demands referred to as "Warburg effect". Hence, interfering with the T-cells' metabolic framework can substantially impact their function. In fact, a dehydrogenase that converts D-2HG to aKG 29 has been identified and could theoretically mediate the entry of high amounts of tumor-derived D-2HG into the T-cells' tricarboxylic acid (TCA) cycle.
Analysis using fluorescent glucose analogues showed an increase in glucose-uptake when T-cells were activated in the presence of 20 mM D-2HG (Fig. 2Ai-Aii) . This effect was timeand dose-dependent (Supplemental Fig. 3) . Interestingly, when D-2HG was washed out and T-cells were cultured for three more days in D-2HG-free medium glucose-consumption returned to initial levels ( Fig. 2Aiii) . At the same time, lactate concentrations as a surrogate for aerobic glycolysis were significantly reduced in the culture medium (Fig. 2B) , again in a timeand dose-dependent manner (Supplemental Fig. 4 ). Surface expression of glucose-transporters (GLUTs) was not affected (Supplemental Fig. 5 ). Since elevation of the intracellular glucose levels can promote global intracellular protein glycosylation, 30 which regulates intracellular signaling, 31 O-GlcNAcylation was determined by flow cytometry using an antibody specific for Olinked N-acetylglucosamine (RL2). Activation of T-cells increased global O-GlcNAcylation and additional D-2HG treatment elevated it even further (Supplemental Fig. 6 ).
Next, we tested whether D-2HG treatment yields glucosedependency. Viability and proliferation of D-2HG-treated T-cells compared to untreated counterparts were not affected by glucose restriction or by pharmacologically blocking the glycolytic key pacemaker molecule hexokinase-2 using 2-deoxyglucose (2DG) (Fig. 2Ci-ii, Supplemental Fig. 7 ). To further elucidate metabolic changes caused by exogenous D-2HG, real-time analyses of oxygen consumption rate (OCR, indicative for mitochondrial respiration) as well as of extracellular acidification rate (ECAR, indicative for aerobic glycolysis) were performed using an extracellular flux analyzer (Fig. 3A) . The sequential addition of inhibitors allowed the calculation of several metabolic parameters as previously detailed. 32 Those analyses revealed significantly increased basal and maximal respiration (Fig. 3Aii) as well as an enhanced ATP-production linked to respiration (Fig. 3Aiii ) upon D-2HG treatment. At the same time, the rate of basal aerobic glycolysis and the capacity to further enhance glycolysis were both significantly reduced (Fig. 3Av-vi) as already indicated by the decreased lactate levels measured in the supernatants (Fig. 2B ). Overall, D-2HG promotes a metabolic switch towards oxidative phosphorylation in activated T-cells (Supplemental Fig. 8 ). Together with the elevated glucose uptake this data suggests an increased glucose flux into the TCA cycle instead of aerobic glycolysis. Indeed, levels of two TCA-intermediates aKG and citrate were significantly increased ( Fig. 3B ). Mitochondrial biogenesis was not enhanced and mitochondria maintained their electrochemical gradient (D~cM) as a surrogate marker for their fitness and coupling efficacy (Supplemental Fig. 9 ). Furthermore, relative gene expression of LDHA (the enzyme that metabolizes pyruvate to lactate) and PDK1 (the enzyme that blocks oxidative decarboxylation of pyruvate thereby preventing its entry into the TCA cycle) were significantly downregulated, while other metabolic genes remained mostly unaffected (Fig. 3C ). The only significantly upregulated gene was GLS, which can metabolize glutamine to glutamate to either replenish the TCA cycle and/or the hexosamine biosynthesis pathway enabling amongst others increased protein glycosylation. Based on previous findings that D-2HG acts as a pro-oxidant 33 and that an increased respiration ( Fig. 3A) can contribute to abundant mitochondrial ROS release 34 we assessed various redox parameters in D-2HG treated T-cells. Flow cytometric analysis of total cellular ROS and mitochondrial superoxide levels by means of CellROX and MitoSOX reagents, respectively, showed no differences between untreated and D-2HG treated T-cells (Supplemental Fig. 10 ). Levels of surface thiols and intracellular glutathione as the major non-enzymatic cellular antioxidants together with the expression of a number of enzymatic antioxidants were also not impacted by D-2HG (Supplemental Figs. 11 and 12 ).
D-2HG has no impact on T-cell IFNg production and senescence, but on Treg frequency
As previously reviewed 28 , T-cell metabolism is tightly interconnected with differentiation and function. First, we evaluated the impact of D-2HG on the T-cells' IFNg production. Despite reduced CD3z chain expression and Zap70 phosphorylation ( Fig. 1D) we observed constant levels of IFNg ( Fig. 4A and Supplemental Fig. 13 ). In line, D-2HG had no impact on IFNg secretion by T-cells activated with allogeneic dendritic cells; however, proliferation was slightly affected (Fig. 4B) . Impact on the CD4
C to CD8 C T-cell ratio and induction of senescence as measured by the surface expression of CD28 (which would be reduced) and CD57 (which would be increased) was not observed (Fig. 4C) . Cytotoxic potency as exemplified by the expression of TNFa and perforin in CD4
C and CD8 C T-cell subsets was not altered either (Supplemental Fig. 14) . Since reduction of aerobic glycolysis accompanied by an increase in oxidative phosphorylation has also been reported to favor regulatory T-cells (Tregs), 35 we evaluated the impact of D-2HG on their frequency. Indeed, D-2HG promoted the frequency of CD25 C CD127 low FoxP3 C naturally occurring-like Tregs (Fig. 4D) . Furthermore, T-cell subsets were defined according to Mahnke cell compartment. Despite reports about the importance of oxidative phosphorylation for T-cell memory formation 37 we did not detect any D2-HG induced changes in the frequencies of na€ ıve, central memory, and effector memory T-cells (Fig. 4E) . Accordingly, the relative expression levels of genes involved in memory T-cell formation were not altered as well (Supplemental Fig. 15 ).
D-2HG activates mTOR signaling but destabilizes HIF-1a resulting in diminished Th17 cell formation
As shown in previous publications, mTOR signaling holds a key role in cellular metabolism. It regulates mitochondrial oxygen consumption, 38 glucose uptake, 39 and nutrient utilization 40 by governing expression and/or activity of metabolic enzymes. 41 In fact, mutant IDH-expressing cell lines showed enhanced mTOR signaling. 42 In line with the increased glucose uptake and mitochondrial respiration we observed enhanced mTOR signaling as suggested by the levels of phosphorylated mTOR (Fig. 5Ai) and its downstream target 4EBP1 (Supplemental Fig. 16 ) while gene expression levels remained unaltered (Supplemental Fig. 17i ). Accordingly, we confirmed a previously reported D-2HG-triggered suppression of the DEP-TOR protein expression that acts as an endogenous mTOR inhibitor (Supplemental Fig. 17ii) . 42 Moreover, treating activated T-cells with 20 mM D-2HG led to a substantial mTOR signaling-addiction. Blocking mTOR by rapamycin had a stronger effect on D-2HG treated T-cells in terms of reducing glucose uptake and diminishing proliferation as compared to their untreated counterparts (Fig. 5Aii-iii) .
The increased mTOR activity is also in line with the aforementioned results on increased O-glycosylation (Supplemental Fig. 6 ). The responsible enzyme O-GlcNAc transferase (OGT) can be controlled by mTOR 31 and both immunofluorescence and Western Blot analyses revealed an increase in OGT level upon D-2HG treatment (Supplemental Fig. 18 ).
Increased mTOR activity was also shown to enhance HIF-1a expression. 43 However, mutated IDH and intracellular 2-HG accumulation promote prolyl hydroxylase activity that targets the HIF-1a protein stability. 44 Treating T-cells with D-2HG reduced HIF-1a protein levels in a time-and dose-dependent manner (Fig. 5B) . HIF-1a gene expression was not impacted (Fig. 5Ci) . The HIF-1a protein reduction was accompanied by a diminished RORC and IL17A gene expression as well as IL-17 A secretion (Fig. 5Ci-ii and Supplemental Fig. 13 ), which are in line with data linking the HIF-1a-aerobic glycolysis axis with Th17 polarization.
45 D 1 Those effects were specific for the oncometabolic D-enantiomer and could not be reproduced with the S-enantiomer of 2HG (Supplemental Fig. 19 ). Chemical induction of HIF-1a using the iron chelator 2,2 0 -dipyridyl (DIP) promoted the gene expression of IL17A and MYC (as another target gene of HIF-1a) (Supplemental Fig. 20) and also restored the IL-17A secretion in the presence of D-2HG (Fig. 5Cii) . Those findings are further corroborated by our observation that D-2HG treatment reduced the frequency of Th17 cells (Fig. 5Di) and also the IL-17 levels within the Th17 population (Fig. 5Dii) . Ultimately, comparing Th17 frequencies within PBMCs from AML patients harboring IDH mutations with wildtype AML counterparts revealed a significantly reduced fraction of IL-17 C CD4 T-cells in the specimen from IDHmutated AML cases (Fig. 5E ).
Discussion
Accumulation of the oncometabolite D-2HG in several tumor entities including AML, 4, 18, 23, 25 and its prognostic impact 23 have raised interest in elucidating its role in cancer development and progression. To date, the vast majority of studies have focused on the autocrine tumor-directed D-2HG effects. D-2HG levels are found up to 100-fold increased in tumor cells and patients' sera and affect pleiotropically the oncogenic potential by epigenetic alterations, 6 enhanced proliferation and differentiation arrest, 8 preferential glutamine utilization, 11, 23 abundant ROS production, 10 interference with mitochondrial metabolism, 12, 13 and mTOR signaling. 42 However, little is known about the effects of D-2HG in shaping the microenvironmental immune components. In fact, tumor cells can alter immune responses by depleting nutrients critical for immune cells such as tryptophan 14 and/or by abundantly releasing immune regulatory metabolic byproducts such as lactic acid. 46 Recent studies suggest (at least indirectly) that D-2HG affects T-cells since IDH mutations were associated with a rather limited intratumoral T-cell infiltration. 16, 47 In fact, treating healthy donor-derived T-cells with D-2HG leads to its intracellular accumulation, although it is non-cell permeable and its mode of transport remains elusive. The biological relevance of this observation is further underlined by the fact that we report for the first time increased D-2HG levels in T-cells isolated from AML patients harboring IDH2 mutations. No negative effects on T-cell viability, proliferation, cytotoxic capacity, and IFNg secretion were observed, which is in contrast to recent findings about the impact of physiologically low levels of the S-enantiomer (S-2HG) on murine CD8
C T-cells under hypoxia upon TCR stimulation showing a decrease in effector cytokine secretion and cell expansion. 48 However, a transient reduction of TCR downstream signaling intensity as exemplified by reduced CD3z and CD25 expression and lower Zap70 phosphorylation levels could be documented. It is likely that the D-2HG-induced effects on TCR signaling are not strong enough to prevent an effective downstream signaling and, thus, still allow achieving a sufficient threshold that triggers e.g. effector cytokine production. Moreover, the observed reduction of T-cell proliferation in MLR in the presence of D-2HG cannot be attributed to a direct influence but may also be indirectly mediated by affecting the dendritic cells.
To date, it is well established that the so-called metabolic signaling holds a key role in governing most aspects of T-cell biology. 28, 49, 50 Activated T-cells undergo metabolic reprogramming that involves the rapid induction of aerobic glycolysis and anabolic reactions. This initial metabolic transition towards aerobic glycolysis is strongly associated with the mTOR pathway. In fact, abundant D-2HG production has been reported to promote a PI3K/AKT-independent mTOR activation. 42 One of the proposed and by us confirmed underlying mechanisms is a D-2HG-mediated reduction of the endogenous negative regulator of mTOR activity called DEPTOR. 42, 51, 52 We observed enhanced levels of mTOR phosphorylation (with unaltered MTOR gene expression together with DEPTOR protein reduction) upon D-2HG application that were accompanied by numerous known downstream phenomena including increased glucose influx, 39 glycosylation, 31 and mitochondrial respiration. 38 Despite enhanced glucose uptake aerobic glycolysis rate was found decreased leading to an overall metabolic skewing towards oxidative phosphorylation suggesting that the glucose flux is mainly fueling the TCA cycle. In fact and in line with this rationale, we found increased levels of TCA cycle intermediates (i.e. aKG and citrate) in D-2HG treated T-cells while expression of pyruvate dehydrogenase kinase 1 (PDK1) that blocks the entry of pyruvate into the TCA cycle was downregulated. Moreover, the TCA cycle could also be additionally replenished by an anaplerotic conversion of the abundant D-2HG to aKG by D-2HG dehydrogenase, 53 which obviously requires further elucidation. Likewise, an anaplerosis of the TCA cycle might occur via glutaminolysis as seen by the significant induction of glutaminase (GLS) by D-2HG treatment. However, T-cells cultured in glutamine-free medium did not show any additional impairments in terms of viability and proliferation upon D-2HG addition (data not shown). Thus, this pathway seems to be dispensable in this context.
In addition to mTOR, metabolic transition towards aerobic glycolysis (upon T-cell stimulation) is driven by HIF-1a that, among other functions, regulates expression of LDHA and PDK1.
54-56 Indeed, we observed HIF-1a protein destabilization upon D-2HG treatment and in line reduced LDHA and PDK1 expression following D-2HG uptake. In fact, earlier publications have shown that IDH mutations together with D-2HG accumulation negatively impact HIF-1a stability by promoting proteasomal degradation after activation of the HIF-1a specific prolyl hydroxylases (EglNs) in malignant cells. 8, 44 Thus, reduced HIF-1a signaling could contribute to the observed metabolic shift away from aerobic glycolysis towards oxidative phosphorylation despite substantial mTOR activation, which otherwise would enhance HIF-1a transcriptional activity in case HIF-1a protein is stably expressed.
43 D 2 As previously mentioned, metabolic signaling is tightly linked to T-cell function and differentiation. Certain metabolic profiles are linked to specific T-cell subsets. Regulatory T-cells (Tregs) as well as memory T-cells have been shown to exhibit a reduced glycolytic activity and to rely more on oxidative phosphorylation (and fatty acid oxidation), while effector T-cell subsets meet their energetic demand by aerobic glycolysis. 49 Thus, we reasoned that the D-2HG induced shift towards oxidative phosphorylation might increase the frequency of Tregs and/or memory T-cells. Indeed, we observed enhanced frequencies of Tregs upon treatment with D-2HG suggesting an additional link between neoplasia-derived D-2HG as a bioactive metabolite and immune modulation. Still, it remains to be elucidated whether enhanced respiratory capacity induced by D-2HG uptake in T-cells increases Treg formation or if Treg survival/persistence is simply favored by elevated levels of tumor-derived D-2HG due to so far unexplored selection mechanisms as seen e.g. for ROS 57, 58 or lactate. 59 On the other hand, we could not detect any changes in the formation of memory T-cells. Furthermore, several studies also demonstrated that an effective anti-tumor functionality of T-cells within the tumor microenvironment is largely depending on their glycolytic activity rather than oxidative phosphorylation in vivo. 60 Although we did not detect impairments of T-cell cytotoxicity in our in vitro system, the influence of D-2HG via metabolic interference on tumor eradication by T-cells in the in vivo situation clearly has to be further examined (in preclinical models). Additionally, enhanced oxidative phosphorylation (caused by enhanced mitochondrial biogenesis and fitness) was also shown to increase the production of ROS 34 which in turn are amongst others important for a proper (antigen-specific) Tcell activation 61, 62 as well as HIF-1a stabilization. 63 However, in our setup we could not detect any changes in neither total cellular nor mitochondrial ROS levels upon D-2HG application. Since ROS production is already induced by (anti-CD2/ CD3/CD28) TCR stimulation in vitro, D-2HG seems to be dispensable for ROS-mediated functions/signaling in this setup. Obviously, this needs to be further explored with in vivo models.
Beyond that, binding of HIF-1a further enhances transcription of Th17-specific genes and finally Th17 polarization. Consequently, D-2HG-mediated HIF-1a destabilization led to reduced expression of the prototypical Th17 transcription factor RORC as well as IL-17A secretion. Both phenomena were restored by chemical stabilization of HIF-1a. Accordingly, D-2HG numerically reduced Th17 cells that additionally showed less IL-17 production (per cell) further strengthening the overall effect. Finally, upon stimulation the frequency of Th17 cells in AML patient-derived samples was reduced in those having AML clones with mutated IDH in contrast to their wildtype counterparts supporting the biological relevance of our findings. Thus, D-2HG contributes to reduced expression of RORC and IL-17 in T-cells thereby diminishing Th17 polarization. However, the role of Th17 cells in AML prognosis and progression is still under debate. [64] [65] [66] While some studies show increased levels of Th17 cells in the peripheral blood of AML patients being associated with poor prognosis, 64, 67 others demonstrate a decreased frequency of Th17 cells and related cytokines in newly diagnosed AML patients with an amelioration of those differences upon chemotherapy. 65, 68 In addition, Th17 cells are known to be an important player in the clearing of infections 69 being one of the major causes of morbidity and mortality in AML. 70 Noteworthy, in contrast to our observations, a recent publication demonstrated a dysbalance between Th17 and Treg cells in favor of Th17 cells driven by induced 2HG accumulation (via transaminase activity or application of cell-permeable dimethyl-2HG) in a murine system of autoimmunity. 17 The differences might be explained by species-related differences or the use of a cell-permeable dimethyl-2HG as an exogenous supply in contrast to the here used non-permeable D-2HG disodium salt.
Taken together, our data suggests that abundantly produced D-2HG in tumors that harbor IDH mutations such as AML and glioma may act (in addition to its oncometabolic potential) as a novel immunometabolic modulator. The T-cells' bioenergetics are shifted towards oxidative phosphorylation and interference with the stability of the pro-glycolytic HIF-1a diminishes the formation of pro-inflammatory Th17 cells and favors the abundance of Tregs. Self-evidently, more studies on the D-2-HG's impact on the various components of the patient's immune system will be necessary in order to put our observation into the context of both anti-tumor immunity as well as protection from infections that are major causes of mortality and morbidity during disease progression.
Materials and methods
Patient material
Peripheral blood mononuclear cells (PBMCs) from both AML patients and healthy donors (HD) were collected upon approval by the local ethics committee (approval number: 219_14B) and participants' written informed consent in accordance with the Declaration of Helsinki.
Antibodies and primers
Antibodies and primers were purchased and used according to the tables 1-4 in supplemental information.
Cell culture
T-cells were isolated from healthy donor-derived human PBMCs using the Pan T-cell Isolation Kit (Miltenyi Biotec, 130-096-535) according to the manufacturer's instructions. Cells were cultured at a density of 1 £ 10 6 / mL in RPMI1640 (ThermoFisher Scientific, 31870074) supplemented with 2 mM L-Glutamine (Sigma-Aldrich, G7513), 10% FCS (PAN BioTech, P30-3302) and 40 U/ mL Penicillin-Streptomycin (ThermoFisher Scientific, 15140122) for 72 h at 37 C and 5% CO 2 atmosphere if not stated otherwise. To stimulate the cells T-cell activation/expansion beads coated with anti-CD2/CD3/CD28 (Miltenyi biotec, 130-091-441) at a bead:T-cell ratio of 1:2 were used.
For restimulation of healthy donor-derived T-cells after 72 h of culture in presence/absence of D-2HG, as well as for ex vivo analysis of Th17 cells from AML PBMCs, cells were treated with 50 ng/ mL PMA and 1 mg/ mL ionomycin in the presence of GolgiPlug TM (as recommended by the manufacturer) for 4-6 h at 37 C and 5% CO 2 .
Flow cytometry
Proliferation was analyzed by staining T-cells with Violet Proliferation Dye 450 (BD Bioscience, 562158) according to the manufacturer's instructions. Cell death was determined by staining with Annexin V-FITC (Biolegend, 640906) using the according buffer (Biolegend, 422201) in combination with 7AAD (Biolegend, 420404) as described by the manufacturer.
All surface and intracellular stainings included a dead cell exclusion using Zombie AquaDye (Biolegend, 423102). Cells were washed in PBS and blocked with Human TruStain FcX TM (Biolegend, 422302) and polyclonal mouse IgG (Dianova, 015-000-003) prior to the staining. Intracellular staining was performed with a Fixation/Permeabilization Solution Kit (BD Bioscience, 555028). Intranuclear staining was performed using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience, 00-5523-00) according to the manufacturer's instructions. Antibodies were incubated at the recommended concentrations for 20 -45 min at 4 C. Glucose uptake was analyzed using the fluorescent glucose analog 6-NBDG (ThermoFisher Scientific, N23106). Cells were washed in PBS and glucose-free medium by centrifugation (300 x g, 6 min, 4 C) and resuspended in 300 mL of glucose-free medium containing 0.3 mM 6-NBDG. Samples were incubated for 15 min at 37 C, 5% CO 2 and subsequently recorded after two washing steps.
To analyze cellular redox-parameters, the anti-oxidative capacity, and the mitochondrial biomass and fitness CellROX 
Extracellular flux analysis
One day prior to measurements, Seahorse XFe96 culture plates (Agilent/Seahorse Bioscience) were coated with Corning TM Cell-Tak Cell and Tissue Adhesive (BD, 354241) according to the manufacturer's recommendations. A Seahorse XFe96 cartridge (Agilent/Seahorse Bioscience) was loaded with XF Calibrant solution (Agilent/Seahorse Bioscience) and incubated overnight in a CO 2 -free atmosphere. The next day, cells were harvested from the culture, washed in assay-specific medium according to the manufacturer's recommendations and viable cells were automatically counted on a Muse Ò Cell Analyzer (Merck Millipore). The cells were seeded at a density of 2.4 £ 10 5 T-cells in 175 mL per well. The ports of the Seahorse cartridge were loaded with 25 mL each of 80 mM glucose, 9 mM oligomycin, and 1 M 2DG for the glycolysis stress test and 20 mL of 10 mM oligomycin, 22 mL of 15 mM FCCP, and 25 mL of 30 mM antimycin A/ rotenone for the mitochondrial stress test. After sensor calibration, assays were run as detailed in the manufacturer's manual by recording ECAR (extracellular acidification rate) and OCR (oxygen consumption rate). Metabolic parameters were obtained from the XF Wave software (Agilent/Seahorse Biosciences) and calculated using Microsoft Excel.
Statistics
Statistics were calculated with Graphpad Prism Version 7 (La Jolla, California, USA). Comparisons between groups were performed using the appropriate statistical methods depending on Gaussian distribution and number of groups and variables, i.e. one-way ANOVA with Tukey's post-hoc test, two-way ANOVA with Bonferroni post-hoc test, unpaired and paired two-tailed t-test, and Mann-Whitney test. 
